Abstract: |
The overall effectiveness of fluorouracil and leucovorin calcium appears to be at least equivalent to fluorouracil therapy alone. The survival experience of patients treated with fluorouracil and leucovorin calcium is similar to those treated with fluorouracil alone. Data suggest that simultaneous administration of fluorouracil and leucovorin calcium may enhance the antitumor activity of fluorouracil even in tumors previously resistant to fluorouracil alone. In most patients, gastrointestinal toxicity and myelosuppression are dose-limiting effects. The precise relationship between the ratio of reduced folate to fluorouracil will require further definition as will the most efficacious route of administration (e.g., intermittent bolus, continuous infusion, or intraperitoneal regimens). |